Risk-reducing strategies #2

Recommendation

Risk-reducing strategies #2

In premenopausal women with breast cancer with a confirmed germline mutation (e.g. BRCA 1/2) that predisposes to an increased risk of breast cancer, discuss risk-reducing strategies (e.g. contralateral risk-reducing mastectomy or endocrine therapy/ risk-reducing medication).

How this guidance was developed

This recommendation was adapted from the CA 2014 guidelines (Australia). The source recommendation was based on a systematic review of the evidence conducted to April 2012 and was graded 'B' (using NHMRC methods) by the source guideline authors. The source recommendation was adapted by removing the specification of BRCA1/2 mutations, specification of gender in the patient population, and the focus on young women and contralateral risk-reducing strategies.

Risk-reducing strategies #2

Recommendation

In premenopausal women with breast cancer with a confirmed germline mutation (e.g. BRCA 1/2) that predisposes to an increased risk of breast cancer, discuss risk-reducing strategies (e.g. contralateral risk-reducing mastectomy or endocrine therapy/ risk-reducing medication).

Principles in action
Image
Patient-centred care
Image
Communication

This recommendation was adapted from the CA 2014 guidelines (Australia). The source recommendation was based on a systematic review of the evidence conducted to April 2012 and was graded 'B' (using NHMRC methods) by the source guideline authors. The source recommendation was adapted by removing the specification of BRCA1/2 mutations, specification of gender in the patient population, and the focus on young women and contralateral risk-reducing strategies.